Skip to content

Toothpastes With Thermal Water for Oral Health

The Effect of Toothpastes Based on Alkaline Thermal Water With and Without Fluorinated Derivative on Gingivitis, Dentin Hypersensitivity, and Oral Hygiene: a Randomized Clinical Trial

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05623761
Enrollment
84
Registered
2022-11-21
Start date
2022-11-01
Completion date
2023-02-15
Last updated
2023-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dentin Hypersensitivity, Gingivitis

Keywords

gingivitis, dentin sensitivity, thermal water, toothpaste, fluoride

Brief summary

The aim of the study is to compare the effect of toothpastes containing thermal water of Castera-Verduzan with 1450 ppm fluoride and without fluorinated derivatives on oral hygiene, gingivitis, and dentin hypersensitivity in young adults.

Detailed description

This will be a double-blind, randomized, two-arm parallel-group study of the effect of toothpastes containing thermal water of Castera-Verduzan with 1450 ppm fluoride and without fluorinated derivatives. The groups will include adults with gingivitis and dentinal hypersensitivity (DH) diagnosed clinically. To assess the effect of the toothpastes, the following parameters will be used: gingival health (modified gingival index, MGI; gingival bleeding index, BI), dentin sensitivity (Shiff's index, VAS), oral hygiene level (Navi-Rustogi index), and salivary pH.

Interventions

DRUGBUCCOTHERM® Sensitive Gums with Fluoride

Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums with Fluoride twice daily for 1 month.

DRUGBUCCOTHERM® Sensitive Gums Fluoride-Free

Toothbrushing using standardised technique and pear-sized amount of toothpaste BUCCOTHERM® Sensitive Gums Fluoride-Free twice daily for 1 month.

Sponsors

I.M. Sechenov First Moscow State Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

The allocation concealment will be performed using sealed containers numbered by a third party (person who will not participate in the study). The toothpastes in white bottles without any titles will be placed in the containers. Each patient will receive a sealed container with a toothpaste on enrolment. Neither patients nor researchers will be aware of the type of the toothpaste used.

Intervention model description

double-blind, randomized, two-arm parallel-group study

Eligibility

Sex/Gender
ALL
Age
20 Years to 25 Years
Healthy volunteers
No

Inclusion criteria

* aged between 20-25 years * signed an approved Informed Consent Form, authorizing the participation in the trial and the use of the results of the trial for educational purposes and for the publication * the diagnosis of gingivitis stated clinically * at least one tooth with the diagnosis of dentin hypersensitivity stated clinically

Exclusion criteria

* medical and pharmacotherapeutic histories that may compromise the protocol (pregnancy or breastfeeding, psychiatric disorders, allergies to toothpastes ingredients, eating disorders) * systemic conditions that are etiologic to dentin hypersensitivity (e.g., chronic acid regurgitation) history of chemotherapy or radiotherapy * taking antibiotic, anti-inflammatory, or anti-coagulant medications 4 weeks prior to or after the baseline visit * oral mucosa pathology * periodontal surgery in the preceding 3 months * orthodontic appliance treatment within previous 3 months * teeth or supporting structures with any other painful pathology or defects * taking any other agents for DH management 4 weeks prior to or after the baseline visit * extensively restored teeth and those with restorations extending into the cervical area * dental bleaching within previous 3 months * subject withdrawal of consent * subject is not compliant with study procedures * adverse Event that in the opinion of the Investigator would be in the best interest of the subject to discontinue study participation

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of gingival inflammation by Modified Gingival Index (MGI)4 weeks after the baselineMGI is used to assess visual symptoms of gingivitis on facial and lingual surfaces of each scorable tooth (whole mouth). Two scores are recorded buccally/labially, two scores lingually/palatally. Values are presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values (i.e., 0-4). Scoring is performed using standard dental light:0=absence of inflammation,1=mild inflammation;slight change in color,little change in color; little change in texture of any portion of the marginal or papillary gingival unit,2=mild inflammation; criteria as above plus the entire marginal or papillar gingival unit,3=moderate inflammation;glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit,4=severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit,spontaneous bleeding,congestion,or ulceration. Lower scores indicate better results.
Evaluation of gingival inflammation by Bleeding Inde4 weeks after the baselineBI is used to assess bleeding elicited on probing as a measure of gingival condition. Gingivae are air dried and examiner assesses bleeding using a probe which is gently inserted into gingival crevice to depth of app 1 mm and run around tooth (angle of app 60 deg to long axis of tooth), gently stretching epithelium while sweeping from interproximal to interproximal along sulcular epithelium. BI is assessed on facial and lingual gingival surfaces of each scorable tooth (whole mouth). 3 scores are recorded buccally/ labially, 3scores lingually/ palatally. All scorable teeth in one quadrant are probed first (app 30 sec) before recording number of gingival units which bleed. Values are presented as means across all tooth surfaces with minimum and maximum scores in agreement with minimum and maximum index values (i.e., 0-2). BI score:0=no bleeding after 30 sec, 1=bleeding upon probing after 30 sec,2=immediate bleeding. Lower scores indicate better results.
Evaluation of DH according to Shiff sensitivity score4 weeks after the baselineFirst, the tooth is isolated by the cotton roll from the adjacent teeth. Next, a blast of air from a standard dental unit syringe at 60 ± 5 psi at 18-22 °C is directed onto the exposed middle 1/3 buccal surface for 1 s at a distance of approximately 10 mm. Then, each patient reports the sensitivity he/she sensed using Schiff Cold Air Sensitivity scale scored from 0 to 3: score 0 means no response, score 1 means response without request of discontinuation of stimulus, score 2 means response with request of discontinuation of stimulus, and score 3 means pain with request of discontinuation of stimuli. Lower scores indicate better results.

Secondary

MeasureTime frameDescription
Evaluation of oral hygiene level according to Navi-Rustogi index4 weeks after the baselineNine sites per facial and lingual tooth surface are assessed, for a maximum 504 sites total (excluding 3rd molars, crowns, and surfaces with cervical restorations). Disclosed plaque is scored in each tooth area as follows: 0 = Absent; and 1 = Present. A mean plaque index (MPI) is calculated for each subject on a whole mouth basis. Lower scores indicate better results.
Evaluation of salivary pH3 minutes after baseline (after toothbrushing)Unstimulated 5 ml whole saliva sample is collected in morning from 10 am to 11 am, two hours after the last meal. Participants refrain from eating, drinking, smoking, or conducting oral hygiene procedures for a minimum of 90 min prior to salivary collection. Participants are comfortably seated, are asked to avoid swallowing saliva and asked to lean forward and spit all the saliva they produced into a graduated test tube until the required volume is collected. The pH is determined immediately after the collection using a digital pH-meter.

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026